ArticleThe American journal of gastroenterology2026
Inflammatory Bowel Disease and Risk of More than 1,500 Comorbidities: A Disease-wide Prediagnostic and Postdiagnostic Phenomic Association Study.
Article in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The exposome and inflammatory bowel disease: a framework for primary and primordial prevention.Nature reviews. Gastroenterology & hepatology · 2026Review
- CLDN8 and ABCA12 define a shared molecular signature in ulcerative colitis-psoriasis comorbidity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionInflammatory bowel disease (IBD) is associated with various extraintestinal manifestations. We aimed to identify comorbidities in IBD and the timing of their development to provide potentially useful insight into the associations with IBD.
methodsWe conducted a population and disease-wide phenomic association study in IBD, using >6 million International Classification of Diseases, Tenth Revision coded healthcare contacts from 10 years before and up-to 17 years after IBD diagnosis to investigate associations with 1,583 comorbidities. To explore diseases with potential etiological significance, we compared association in the prediagnostic and the postdiagnostic periods. We corrected also for multiple-testing. These estimates were validated with publicly available data from Finland.
resultsWe identified 312 significant associations with 125 appearing before diagnosis. Risk of extraintestinal manifestations was increased up to 10 years before IBD diagnosis, such as psoriasis (OR CD : 2.58 95% confidence interval: [2.00-3.31]; OR UC : 1.54 [1.26-1.88]) and reactive arthropathies (OR CD : 2.07 [1.42-2.96]; OR UC : 1.42 [1.08-1.84]). Risk of cardiometabolic and neuropsychological disorders was increased both prediagnostically and postdiagnostically. Potential treatment sequelae, such as osteoporosis (HR CD : 2.56 [2.30-2.86]; HR UC : 1.92 [1.79-2.07]) were primarily seen postdiagnostically. In only 15.7% (44/281) and 11.4% (35/301) of comorbidities in Crohn's disease and ulcerative colitis, respectively, did we observe heterogeneity between Denmark and Finland. DISCUSSION: Findings demonstrate that IBD is a multisystemic disease, particularly manifesting with metabolic, immune, and neuropsychological disorders, up to 10 years before diagnosis. We find evidence for the generality of these findings with an international comparison. Diseases of etiological interest warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.